A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 9, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Dexpramipexole Dihydrochloride

Administration of dexpramipexole tablet

Trial Locations (23)

15801

Research Site US-10001-002, DuBois

19140

Research Site US-10001-013, Philadelphia

21224

Research Site US-10001-020, Baltimore

28054

Research Site US-10001-007, Gastonia

28277

Research US-10001-010, Charlotte

28293

Research Site US-10001-025, Charlotte

29732

Research Site US-10001-012, Rock Hill

32803

Research Site US-10001-030, Orlando

43215

Research Site US-10001-004, Columbus

46324

Research Site US-10001-021, Hammond

48336

Research Site US-10001-024, Farmington Hills

50266

Research Site US-10001-033, Des Moines

61820

Research Site 10001-032, Champaign

63110

Research Site US-10001-001, St Louis

63301

Research Site US-10001-005, Saint Charles

72032

Research Site US-10001-017, Conway

75069

Research Site 10001-026, McKinney

75110

Research Site US-10001-009, Corsicana

77030

Research Site US-10001-038, Houston

91324

Research Site US-10001-022, Northridge

92663

Research Site US-10001-008, Newport Beach

92683

Research Site US-10001-016, Westminster

02914

Research Site US-10001-023, East Providence

Sponsors
All Listed Sponsors
lead

Areteia Therapeutics

INDUSTRY